Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SRP+iPRF

PreclinicalBiologic

MMedical University of Bialystok

SRP+iPRF is one of 23 biologic programs targeting Periodontitis. It is currently in Preclinical.

1

Indications

1

Total Trials

1

Active Trials

22

Competitors

Pipeline

Status by Indication[3][1]

Indication

PeriodontitisActive, not recruiting

PeriodontitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

138 competitors in Periodontitis

#DrugCompanyPhaseTrials

Peridex

DDexcel Pharma Technologies Ltd.

Acanya

Curcumin

Bayer Aspirin

Calcium Hydroxide

MMansoura University

Docosahexaenoic Acid

MMicelle BioPharma Inc

Calcium Intravenous Infsuion

MMansoura University

Minocycline Hcl

Boswellia

MMansoura University

Metapex

AAga Khan University

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Periodontitis1 trial

Evaluation of the Influence of PRF (Platelet-rich Fibrin) on the Clinical Parameters and the Concentration of Selected Inflammation Mediators in GCF (Gingival Crevice Fluid) of Patients With Periodontitis

Active, not recruiting·MMedical University of Bialystok·N/A·NCT06920849·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SRP+iPRF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SRP+iPRF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SRP+iPRF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Bialystok company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: MMedical University of Bialystok

Related News